AFT Forsyth & Company Inc. Acquires Shares of 3,753 Thermo Fisher Scientific Inc. $TMO

AFT Forsyth & Company Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,753 shares of the medical research company’s stock, valued at approximately $2,175,000. Thermo Fisher Scientific accounts for 0.9% of AFT Forsyth & Company Inc.’s investment portfolio, making the stock its 22nd biggest position.

A number of other institutional investors also recently bought and sold shares of TMO. High Note Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the period. Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Olistico Wealth LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Core Wealth Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $30,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 1.4%

TMO stock opened at $468.80 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company’s 50 day simple moving average is $479.14 and its 200-day simple moving average is $527.68. The firm has a market capitalization of $174.22 billion, a PE ratio of 25.77, a P/E/G ratio of 2.08 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter last year, the business earned $5.15 earnings per share. Thermo Fisher Scientific’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Morgan Stanley restated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $608.95.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.